

DUPIXENT[®]
(dupilumab) Injection 300mg

**INTRODUCING DUPIXENT, THE FIRST AND ONLY
FDA-APPROVED TREATMENT FOR ADULTS WITH**

BULLOUS PEMPHIGOID (BP)

Patient portrayal

INDICATION

DUPIXENT is a prescription medicine used to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age.

Please see Important Safety Information throughout and [links to](#) full [Prescribing Information](#) and [Patient Information](#) [\[in the back pocket\]](#).

WHAT IS BULLOUS PEMPHIGOID (BP)?

Bullous pemphigoid is a rare chronic-relapsing autoimmune skin condition that causes fluid-filled blisters and other inflammatory lesions. It is caused by the immune system attacking a layer of tissue in the skin. These outbreaks could be triggered by certain medications. The reason why this happens is not fully understood.

SIGNS AND SYMPTOMS OF BP INCLUDE:

- ▶ Recurring phases of:
 - ▶ Rashes
 - ▶ Blisters and painful sores
- ▶ Intense itchiness

While blisters may occur anywhere, they commonly form near creases in the skin.



IMPORTANT SAFETY INFORMATION: Please see Important Safety Information throughout and [links to full Prescribing Information and Patient Information \[in the back pocket\]](#).

HOW DO YOU TREAT BP?

DUPIXENT is approved by the FDA to treat bullous pemphigoid in adults 18 years of age and older.

It targets a source of underlying inflammation that may be a cause of BP. The result is a chance at sustained remission, less itch, and a reduction in the use of steroids.

DUPIXENT was studied in a 52-week trial with 106 adults with BP. DUPIXENT helped patients with BP achieve control of their signs and symptoms, also known as sustained remission, at week 36. That means there are no new blisters, old ones are healing, and steroids are tapered off by week 16, with no relapses from week 16 to week 36, and no rescue treatment through week 36.

AT 36 WEEKS

5X

MORE PATIENTS HAD SUSTAINED REMISSION

(20% on DUPIXENT vs 4% not on placebo)

4X

MORE PATIENTS HAD LESION IMPROVEMENT*

(41% on DUPIXENT vs 10% on placebo)

3.5X

MORE PATIENTS EXPERIENCED LESS ITCH

(40% on DUPIXENT vs 11% on placebo)

~25%

REDUCTION IN THE TOTAL AMOUNT OF ORAL STEROIDS NEEDED

(5.65g for patients on DUPIXENT vs 7.32g on placebo)

The most common side effects in BP were (incidence $\geq 2\%$): arthralgia, conjunctivitis, constipation, blurred vision, herpes viral infections, injection site reactions, keratitis.

*Lesion improvement defined as 90 percent reduction in number, size of lesions, and extent of affected areas.

ABOUT DUPIXENT® (dupilumab)

- ▶ It's the first FDA-approved treatment proven to help adults with BP reduce the use of steroids
- ▶ It works continuously between doses to manage symptoms proactively
- ▶ It's not a steroid or immunosuppressant
- ▶ It doesn't require initial or routine blood work, according to the Prescribing Information
- ▶ It has no known drug-to-drug interactions

DUPIXENT IS A TREATMENT THAT

- » TARGETS A KEY SOURCE OF UNDERLYING INFLAMMATION THAT MAY CONTRIBUTE TO BP
- » WAS STUDIED IN A CLINICAL TRIAL THAT SHOWED IT CAN TREAT BP, AND IN MANY CASES, OFFER SUSTAINED REMISSION

IMPORTANT SAFETY INFORMATION: Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you: have eye problems; have a parasitic (helminth) infection; are scheduled to receive any vaccinations. You should not receive a "live vaccine" right before and during treatment with DUPIXENT.

have eye problems; have a parasitic (helminth) infection; are scheduled to receive any vaccinations. You should not receive a "live vaccine" right before and during treatment with DUPIXENT; are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to <https://mothertobaby.org/ongoing-study/dupixent/>; are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

HOW DUPIXENT IS TAKEN

DUPIXENT is a biologic medicine given under the skin (subcutaneous injection). It can be self-administered, given by a caregiver at home, or if you prefer, your healthcare provider can administer it at their office. You can even take it with oral corticosteroids and taper off of them as you and your doctor see fit.



PRE-FILLED PEN



PRE-FILLED SYRINGE

Adult patients begin DUPIXENT with an initial dose of 600 mg (two 300-mg injections) followed by 300 mg every other week. Do not try to take DUPIXENT until you are properly trained by your doctor.



USE THE CAMERA ON YOUR PHONE TO SCAN [OR CLICK HERE] TO WATCH SUPPLEMENTAL TRAINING VIDEOS ON HOW TO ADMINISTER DUPIXENT

IMPORTANT SAFETY INFORMATION:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines or if you have atopic dermatitis and asthma and use an asthma medicine.

Please see Important Safety Information throughout and [links to] full Prescribing Information and Patient Information [in the back pocket].

HELPFUL RESOURCES FOR YOU, EVERY STEP OF THE WAY

DUPIXENT MyWay is a patient support program designed to help you start DUPIXENT as quickly as possible and stay on track with your treatment.

ENROLLING IN **DUPIXENT MyWay**[®] IS FREE AND SIMPLE

Contact us directly at [1-844-DUPIXENT (1-844-387-4936) Option 1, Monday–Friday, 8 PM–9 PM ET].

Once enrolled in the program, you'll have a dedicated Case Manager who can provide:



Help with understanding your insurance coverage for DUPIXENT



Financial assistance, including copay support, if eligible



Connection to a **DUPIXENT MyWay** Nurse Educator who can offer supplemental injection training in person, virtually, or by the phone



Tips and tools to help you manage treatment

IMPORTANT SAFETY INFORMATION: Please see Important Safety Information throughout and [links to] full Prescribing Information and Patient Information [in the back pocket].

OPTIONS FOR FINANCIAL SUPPORT



The **DUPIXENT MyWay Copay Card Program** may help eligible patients with commercial health insurance cover out-of-pocket costs for DUPIXENT.*

The **DUPIXENT MyWay Patient Assistance Program**[†] may be able to help you if you do not have health insurance, if you are experiencing difficulty paying for your DUPIXENT treatment, or have Medicare Part D.

Find out if you qualify by speaking with a **DUPIXENT MyWay Case Manager** at [1-844-DUPIXENT (1-844-387-4936) Option 1].



USE THE CAMERA ON YOUR PHONE TO SCAN [OR CLICK HERE] TO LEARN MORE ABOUT **DUPIXENT MyWay**

*Subject to the program maximum per patient per calendar year. Approval is not guaranteed. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients' out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.

[†]Eligible commercial patients and Medicare patients without the Part D (pharmacy) benefit may receive free shipments of up to an 84- day supply of DUPIXENT (for up to 12 months). Patients may reapply after 12 months if they still meet the eligibility criteria. Patients with Medicare Part D who meet eligibility criteria must reapply for the Patient Assistance Program each calendar year, or by December 31st for eligibility consideration for the following year. The assistance period for Medicaid patients varies based on the eligibility criteria. Please note that DUPIXENT MyWay reserves the right to make eligibility determinations, monitor participation, ensure equitable product availability, and modify or discontinue the DUPIXENT MyWay Patient Assistance Program at any time without notice.

IMPORTANT SAFETY INFORMATION: Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT[®]
(dupilumab) Injection 300mg

**HELP
HEAL
YOUR
SKIN
FROM
WITHIN**[™]



SCAN WITH YOUR PHONE CAMERA,
[CLICK HERE,] OR VISIT [DUPIXENT.COM/BP](https://www.dupixent.com/bp)
TO LEARN MORE

➤ TALK TO YOUR DOCTOR ABOUT DUPIXENT TODAY

IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including: Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue, or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area, **Joint aches and pain.** Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.

The most common side effects in patients with eczema include injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, dry eye, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia)

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It's an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT.

Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it's recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see [links to] full Prescribing Information and Patient Information [in the back pocket].

sanofi | **REGENERON**[®]



© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved.
DUPIXENT[®] and *DUPIXENT MyWay*[®] are registered trademarks of
Sanofi Biotechnology. US.DUP.25.03.0417 6/25